<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768326</url>
  </required_header>
  <id_info>
    <org_study_id>11613A</org_study_id>
    <secondary_id>EudraCT 2006-003739-57</secondary_id>
    <nct_id>NCT00768326</nct_id>
  </id_info>
  <brief_title>Efficacy of Lu 31-130 in Patients With Schizophrenia</brief_title>
  <official_title>A Double-blind, Randomised, Parallel-group, Placebo-controlled Study of the Safety, Tolerability and Efficacy Following Sequential Dose Regimens of Lu 31-130 to Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose with the study is to evaluate the efficacy and safety of Lu 31-130 in
      patients suffering from schizophrenia compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a serious and disabling mental disorder that affects approximately 1% of the
      world's population. Antipsychotic drugs remain the cornerstone in the pharmacotherapy of
      schizophrenia. However, none of the available drugs is ideal, in particular because of their
      complex safety profile and the limited effectiveness against certain symptoms of the disease.
      Thus, only one dimension of the morbidity, that is, the positive symptoms, can be expected to
      respond to treatment whereas negative symptoms and cognitive deficits are, at best, only
      marginally targeted.

      Given this, there is no doubt that the current antipsychotic drugs leave much room for
      improvement and call for new, more effective pharmacotherapies in the treatment of
      schizophrenia. In the current study, patients suffering from schizophrenia and experiencing
      clinically significant symptoms of the disease will be included. In the current study,
      eligible patients will be randomised in a 2:1 ratio to blinded treatment with either Lu
      31-130 (3, 5, 7, 10 or 14 mg/day) or placebo for 8 weeks. The study includes 5 parts with
      increasing doses of Lu 31-130 (Part A [3 mg/day], B [5 mg/day], C [7 mg/day], D [10 mg/day],
      and E [14 mg/day]). A decision to initiate Part B [5 mg/day of Lu 31-130], C [7 mg/day of Lu
      31-130] or D [10 mg/day of Lu 31-130] will be based on safety and tolerability of the
      previous study part. Dependent on the safety, tolerability and PK data from Part D the study
      may proceed with Part E. The efficacy and the safety of Lu 31-130 will be evaluated in
      comparison to the pooled placebo group from all 5 study parts.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Adverse events, clinical safety laboratory tests (including liver biochemistry tests), metabolic parameters (including blood lipids, blood glucose weight, waist circumference), abnormal movements</measure>
    <time_frame>8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in the Positive and Negative Syndrome Scale (PANSS) score from baseline to Week 8 as compared to placebo, change from baseline in Clinical Global Impression/Improvement (CGI-S/I) scores as compared to placebo</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Zicronapine. Study Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Zicronapine. Study Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Zicronapine. Study Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Zicronapine. Study Part D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Zicronapine. Study Part E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2A, 2B, 2C, 2D, 2E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zicronapine</intervention_name>
    <description>Study Part A:
3mg; orally, film-coated tablets, once daily, 8 weeks</description>
    <arm_group_label>Zicronapine. Study Part A</arm_group_label>
    <other_name>Lu 31-130</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zicronapine</intervention_name>
    <description>Study Part B:
5mg; orally, film-coated tablets, once daily, 8 weeks</description>
    <arm_group_label>Zicronapine. Study Part B</arm_group_label>
    <other_name>Lu 31-130</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zicronapine</intervention_name>
    <description>Study Part C:
7mg; orally, film-coated tablets, once daily, 8 weeks</description>
    <arm_group_label>Zicronapine. Study Part C</arm_group_label>
    <other_name>Lu 31-130</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zicronapine</intervention_name>
    <description>Study Part D:
2 x 5mg; orally, film-coated tablets, once daily, 8 weeks</description>
    <arm_group_label>Zicronapine. Study Part D</arm_group_label>
    <other_name>Lu 31-130</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zicronapine</intervention_name>
    <description>Study Part E:
2 x 7mg; orally, film-coated tablets, once daily, 8 weeks</description>
    <arm_group_label>Zicronapine. Study Part E</arm_group_label>
    <other_name>Lu 31-130</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study Part A, B, C, D and E:
Placebo; orally, film-coated tablets, once daily, 8 weeks</description>
    <arm_group_label>2A, 2B, 2C, 2D, 2E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has a primary diagnosis of schizophrenia

          -  The patient experiences clinically significant symptoms

          -  The patient did not experience an acute exacerbation requiring hospitalisation within
             the last 6 months

          -  The patient's medication has been stable for at least 4 weeks prior screening

          -  The subject has normal serum values of parameters associated with liver function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DE001</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2008</study_first_submitted>
  <study_first_submitted_qc>October 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Antipsychotic</keyword>
  <keyword>Lu 31-130</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_id>2006-003739-57</doc_id>
      <doc_type>EMA EudraCT Results</doc_type>
      <doc_url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003739-57/results</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

